CANTARGIA
The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia
CANTARGIA
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2010-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.cantargia.com
Total Employee:
1+
Status:
Active
Contact:
46 4 62 75 62 60
Email Addresses:
[email protected]
Total Funding:
25.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Font Awesome Apache Microsoft Exchange Online
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
LUBio Science
LUBio Science investment in Venture Round - Cantargia
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Venture Round - Cantargia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-08 | Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer |
| 2020-06-23 | Cantargia strengthens management team with VP Regulatory Affairs and VP CMC |
| 2020-02-25 | Cantargia appoints Dr. Ignacio Garcia-Ribas as Chief Medical Officer |
Official Site Inspections
http://www.cantargia.com Semrush global rank: 6.61 M Semrush visits lastest month: 931
- Host name: srv08.style4.se
- IP address: 46.246.39.203
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Cantargia"
Cantargia - Crunchbase Company Profile & Funding
Organization. Cantargia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target …See details»
About Cantargia's Corporate Governance | Cantargia
Cantargia is a Swedish public limited company. Corporate governance in the Company is based on Swedish law, Cantargia’s Articles of Association and internal governing documents, …See details»
Cantargia reports organisational change
Jul 22, 2024 About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has …See details»
Leaders in antibody technology targeting IL1RAP | Cantargia
Oct 14, 2024 2024-12-11 Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer …See details»
Cantargia AB Company Overview, Contact Details & Competitors
Nov 6, 2024 Cantargia AB launched preclinical data on anti-inflammatory IL1RAP-binding antibody CAN10 on Mar 1st '22. Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today …See details»
Cantargia - Overview, News & Similar companies | ZoomInfo.com
Who is Cantargia. Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a …See details»
Cantargia - Contacts, Employees, Board Members, Advisors
Cantargia has 11 current employee profiles, including Co-Founder Marcus Jaras. Cantargia has 4 board members and advisors, including Thoas Fioretos . ContactsSee details»
Cantargia - Company Profile - Tracxn
Nov 18, 2024 Cantargia - Developer of antibody-based therapy for the treatment of solid tumors and cancers. Public Company. Raised a total funding of $1M over 3 rounds from 11 investors. …See details»
Cantargia Company Profile - Office Locations, Competitors ... - Craft
Cantargia is a biotechnology company that specializes in the development of pharmaceuticals for various types of cancer, autoimmune and inflammatory diseases. It develops CAN04, an …See details»
Company Cantargia AB Nasdaq Stockholm - MarketScreener.com
Dec 31, 2015 Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a …See details»
Cantargia - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name ... Post-IPO Equity - Cantargia — obfuscated. obfuscated — Jul 5, 2013: Venture …See details»
Cantargia AB: Governance, Directors and Executives & Committees ...
Dec 31, 2013 Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a …See details»
Financial Reports and Results - Cantargia
May 21, 2024 Access Cantargia's financial reports, including annual reports and quarterly updates. Inform yourself about our financial progress and future plans. About. About Cantargia …See details»
Org Chart Cantargia - The Official Board
Cantargia has 12 executives. Cantargia; Please confirm your deletion . Delete or Cancel . Unfortunately, you don't own enough credit to see this new org chart. To continue, you can …See details»
Company Cantargia AB BOERSE MUENCHEN - MarketScreener.com
Dec 31, 2015 Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a …See details»
Cantargia - VentureRadar
Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of …See details»
Cantargia AB - Drug pipelines, Patents, Clinical trials - Synapse
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its …See details»
Ledande inom antikroppsbaserad behandling mot IL1RAP
Oct 14, 2024 Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för behandling av såväl cancer som autoimmuna och …See details»
Cantargia - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Dec 10, 2024 Cantargia uses 12 technology products and services including HTML5, F5 NGINX, and Vimeo, according to G2 Stack. Cantargia is actively using 28 technologies for its website, …See details»
Cantargia
Cantargia is a small and agile company that is continuously growing in pace with new projects and new employees. The culture is characterized by entrepreneurial mindset and team spirit with …See details»